Micreos

About Micreos

Micreos is a pioneering company in the healthcare sector, specializing in the development of targeted antibacterial products designed to replace traditional antibiotics. The company operates primarily in the pharmaceutical and biotechnology markets, focusing on innovative solutions to combat bacterial infections without harming beneficial bacteria. This approach is particularly relevant in the context of rising antibiotic resistance, which is a significant global health concern.

Micreos serves a diverse range of clients, including healthcare providers, dermatologists, and patients suffering from bacterial infections and conditions like eczema. Their products are designed to selectively target harmful bacteria, such as Staphylococcus aureus, without affecting the beneficial bacteria that are crucial for maintaining a healthy microbiome. This selective targeting is achieved through their proprietary endolysin technology, which has been proven effective in clinical studies.

The company's business model revolves around the research, development, and commercialization of these targeted antibacterial products. They generate revenue through the sale of their products to healthcare institutions and direct consumers. Additionally, Micreos may engage in partnerships and licensing agreements with other pharmaceutical companies to expand the reach and application of their technology.

Micreos has garnered significant recognition for its innovative approach, including being named Europe's most relevant innovation in 2018 at the Finals Ideas from Europe. This accolade underscores the company's leadership in the field of antibiotic alternatives and its potential to revolutionize how bacterial infections are treated.

In summary, Micreos is at the forefront of developing next-generation antibacterial solutions that address the critical issue of antibiotic resistance while preserving the beneficial bacteria essential for human health.